Life sciences attorney Christin Carey explains why mid-size branded pharma and specialty biotech companies need to think beyond trade strategy when responding to the Trump administration's 100% tariffs on imported branded drugs. Nearly every supply chain adjustment, from moving a manufacturing site to switching an API supplier, triggers a regulated post-approval change requiring FDA review. Christin outlines the steps companies should take now before the regulatory clock runs out.

FDA in Five: Drug Tariffs are an FDA Problem